ICD-10-CM Billable Code

J67.1

Bagassosis

Clinical Classification Guidelines

Inclusion Terms

  • Bagasse disease
  • Bagasse pneumonitis

Medical Intelligence & Overview

Bagassosis, also known as Bagasse pneumonitis, is a rare respiratory condition caused by an allergic reaction to dust from bagasse, the fibrous residue remaining after crushing sugarcane. This condition primarily affects individuals who work in sugar mills or environments where they are exposed to excessive amounts of bagasse dust. Recognized under ICD-10 code J67.1, bagassosis is a type of hypersensitivity pneumonitis, an immune-mediated inflammation of the lung tissue triggered by inhaled organic dusts. Understanding the causes, symptoms, and potential management of bagassosis is crucial for at-risk populations, especially those involved in the sugarcane industry.

Causes & Symptoms

Clinical Causes: Inhalation of dust from bagasse, the fibrous byproduct of sugarcane processing. Prolonged or repeated exposure to poorly ventilated environments with high levels of bagasse dust. Occupational exposure among workers in sugar mills, plantations, or facilities handling bagasse. Inadequate use of personal protective equipment (PPE) during handling or processing of bagasse. Sensitization to proteins and other organic materials present within the bagasse dust.

Key Symptoms: Persistent cough, often dry in nature. Shortness of breath, especially during physical activity. Chest tightness or discomfort. Fatigue and general malaise. Low-grade fever, particularly during active episodes. Wheezing or noisy breathing in some cases. Episodes that tend to worsen with ongoing exposure and improve with rest or removal from exposure.

Diagnostic & Treatment

Diagnosis Path: Diagnosing bagassosis involves a comprehensive assessment including a detailed occupational history to identify exposure to bagasse dust. Pulmonary function tests can reveal restrictive lung patterns and decreased lung capacity. Imaging studies, such as chest X-rays or high-resolution CT scans, might display characteristic patterns like ground-glass opacities or fibrosis in chronic cases. Blood tests may show elevated eosinophils or specific immune responses, while skin prick testing or specific IgE testing can support evidence of hypersensitivity. Occasionally, lung biopsies are performed for definitive diagnosis, especially in ambiguous cases. The goal is to differentiate bagassosis from other respiratory conditions like asthma, COPD, or other forms of pneumonitis.

Treatment Protocols: Management of bagassosis primarily involves avoiding further exposure to bagasse dust. This might include the use of personal protective equipment like masks or respirators, improving ventilation in affected work environments, and implementing safety protocols. Corticosteroids may be prescribed to reduce inflammation and manage acute symptoms. In cases of chronic or severe disease, respiratory rehabilitation and supportive therapies could be beneficial. Early recognition and prompt removal from exposure are key to preventing disease progression and promoting lung recovery. Workers should also be monitored periodically for lung function and symptoms to detect any early signs of relapse or worsening condition.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is J67.1 a billable ICD-10 code?
Yes, J67.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report J67.1?
Clinical documentation must specify the nature of Bagassosis and any associated comorbidities for accurate reporting.

Cite this Clinical Reference

Related Diagnosis Codes

Clinical Meta Tags

bagassosis